James Saccaro
James Saccaro's purchase track record
James Saccaro has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/1/2026 | GEHC | $201K | +11.5% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Transaction History
| GEHC | ▲ Buy | Open Market | 3,310 | $201K | 5/1/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 12,475 | $0 | 3/2/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 22,610 | $0 | 2/12/2026 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 8,570 | $679K | 2/12/2026 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 948 | $75K | 2/1/2026 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,498 | $110K | 9/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,740 | $128K | 9/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 9,712 | $685K | 6/1/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 11,278 | $0 | 3/3/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 934 | $82K | 2/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,740 | $148K | 9/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 8,998 | $702K | 6/1/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 10,245 | $0 | 3/1/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 43,843 | $0 | 6/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 5,950 | $0 | 6/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 11,900 | $0 | 6/1/2023 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 1,061 | $42K | 3/2/2023 | View on chart |
| BAX | ▲ Buy | Grant | 22,217 | $0 | 3/1/2023 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 1,059 | $43K | 2/13/2023 | View on chart |
| BAX | ▲ Buy | Grant | 3,362 | $0 | 2/13/2023 | View on chart |
| BAX | ▲ Buy | Grant | 10,702 | $0 | 3/2/2022 | View on chart |
| BAX | ▲ Buy | Grant | 7,534 | $0 | 2/10/2022 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 4,807 | $422K | 2/10/2022 | View on chart |
| BAX | ▲ Buy | Grant | 2,607 | $0 | 2/10/2022 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 34,678 | $2.7M | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron
GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.